AlloVir (ALVR) Competitors $9.28 +0.28 (+3.11%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ALVR vs. NLTX, PRQR, HURA, ZNTL, IKT, SCPH, CRDF, CGEN, SLN, and CYBNShould you be buying AlloVir stock or one of its competitors? The main competitors of AlloVir include Neoleukin Therapeutics (NLTX), ProQR Therapeutics (PRQR), TuHURA Biosciences (HURA), Zentalis Pharmaceuticals (ZNTL), Inhibikase Therapeutics (IKT), scPharmaceuticals (SCPH), Cardiff Oncology (CRDF), Compugen (CGEN), Silence Therapeutics (SLN), and Cybin (CYBN). These companies are all part of the "pharmaceutical products" industry. AlloVir vs. Neoleukin Therapeutics ProQR Therapeutics TuHURA Biosciences Zentalis Pharmaceuticals Inhibikase Therapeutics scPharmaceuticals Cardiff Oncology Compugen Silence Therapeutics Cybin Neoleukin Therapeutics (NASDAQ:NLTX) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, community ranking, profitability and dividends. Do institutionals and insiders believe in NLTX or ALVR? 52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by insiders. Comparatively, 32.1% of AlloVir shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has preferable earnings & valuation, NLTX or ALVR? AlloVir is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeoleukin TherapeuticsN/AN/A-$57.56M-$3.11-5.34AlloVirN/AN/A-$190.42M-$0.88-10.55 Does the MarketBeat Community prefer NLTX or ALVR? Neoleukin Therapeutics received 23 more outperform votes than AlloVir when rated by MarketBeat users. However, 57.45% of users gave AlloVir an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote. CompanyUnderperformOutperformNeoleukin TherapeuticsOutperform Votes5045.87% Underperform Votes5954.13% AlloVirOutperform Votes2757.45% Underperform Votes2042.55% Is NLTX or ALVR more profitable? Neoleukin Therapeutics' return on equity of -37.22% beat AlloVir's return on equity.Company Net Margins Return on Equity Return on Assets Neoleukin TherapeuticsN/A -37.22% -30.91% AlloVir N/A -71.03%-61.27% Which has more volatility and risk, NLTX or ALVR? Neoleukin Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Does the media favor NLTX or ALVR? In the previous week, AlloVir had 6 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 7 mentions for AlloVir and 1 mentions for Neoleukin Therapeutics. Neoleukin Therapeutics' average media sentiment score of 0.00 beat AlloVir's score of -0.14 indicating that Neoleukin Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neoleukin Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AlloVir 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral SummaryNeoleukin Therapeutics beats AlloVir on 7 of the 12 factors compared between the two stocks. Get AlloVir News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALVR vs. The Competition Export to ExcelMetricAlloVirBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.07B$2.96B$5.21B$9.15BDividend YieldN/A1.91%5.13%4.03%P/E Ratio-10.5545.5588.7917.36Price / SalesN/A276.211,241.0977.31Price / CashN/A192.9043.7535.97Price / Book7.253.965.314.79Net Income-$190.42M-$41.02M$122.54M$225.00M7 Day Performance-1.59%0.19%0.60%2.62%1 Month Performance-0.13%-1.72%2.55%3.81%1 Year Performance-40.66%-2.23%25.29%20.10% AlloVir Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALVRAlloVir1.5679 of 5 stars$9.28+3.1%N/A-40.7%$1.07BN/A-10.55110Stock SplitNLTXNeoleukin TherapeuticsN/A$19.58-8.9%N/A-45.0%$184.01MN/A-6.3090High Trading VolumePRQRProQR Therapeutics2.7586 of 5 stars$2.25-7.0%$8.83+292.6%+13.9%$183.78M$17.88M-7.03180HURATuHURA BiosciencesN/A$4.31-11.1%$13.00+201.6%N/A$182.25MN/A0.00N/APositive NewsZNTLZentalis Pharmaceuticals2.766 of 5 stars$2.55-7.3%$10.00+292.2%-82.6%$181.73M$40.56M-1.02160Positive NewsIKTInhibikase Therapeutics1.6613 of 5 stars$2.70-8.5%$6.50+140.7%+58.1%$181.42M$260,000.00-1.016Positive NewsGap DownSCPHscPharmaceuticals3.335 of 5 stars$3.56+4.7%$15.00+321.3%-38.6%$178.14M$30.28M-1.8730CRDFCardiff Oncology2.1485 of 5 stars$3.48-3.6%$10.33+196.9%+128.5%$177.95M$688,000.00-3.7020Positive NewsCGENCompugen2.4353 of 5 stars$1.99+21.0%$4.00+101.5%+16.0%$177.14M$59.85M99.2570High Trading VolumeSLNSilence Therapeutics2.1072 of 5 stars$5.90-1.5%$57.20+869.5%-72.2%$176.58M$16.25M-3.76100CYBNCybin2.9391 of 5 stars$8.79-1.1%$138.00+1,470.0%N/A$175.73MN/A-1.3250Positive News Related Companies and Tools Related Companies NLTX Alternatives PRQR Alternatives HURA Alternatives ZNTL Alternatives IKT Alternatives SCPH Alternatives CRDF Alternatives CGEN Alternatives SLN Alternatives CYBN Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALVR) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredTop Picks for Trump’s Pro-Crypto AmericaThe Crypto ETF Windfall: 27 Experts Tell All (Free) Don't miss your chance to see exactly what crypto's eli...Crypto 101 Media | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AlloVir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AlloVir With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALVR Stock Alerts